The tariff classification of Cabozantinib (CAS No. 849217-68-1) in bulk powder form, from Finland
Issued July 23, 2020 by U.S. Customs and Border Protection.
Tariff classification
HTS codes: 2933.49.2600
Headings: 2933
Product description
Cabozantinib is an antineoplastic agent and a receptor tyrosine kinase inhibitor with activity against MET, VEGFR2, FLT3, c-KIT, and RET. It is indicated for the treatment of medullary thyroid cancer and a second line treatment for renal cell carcinoma.
CBP rationale
The applicable subheading for the Cabozantinib in bulk powder form will be 2933.49.2600, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Heterocyclic compounds with nitrogen hetero-atom(s)only: Compounds containing in the structure a quinoline or isoquinoline ring-system (whether or not hydrogenated), not further fused: Other: Other: Drugs: Other.
Full text
N312770 July 23, 2020 CLA-2-29:OT:RR:NC:N3:138 CATEGORY: Classification TARIFF NO.: 2933.49.2600 Ms. Robyn K. Brunciak Interchem Corporation 120 Route 17 North Paramus, NJ 07652 RE: The tariff classification of Cabozantinib (CAS No. 849217-68-1) in bulk powder form, from Finland Dear Ms. Brunciak: In your letter dated June 25, 2020, you requested a tariff classification ruling. Cabozantinib is an antineoplastic agent and a receptor tyrosine kinase inhibitor with activity against MET, VEGFR2, FLT3, c-KIT, and RET. It is indicated for the treatment of medullary thyroid cancer and a second line treatment for renal cell carcinoma. The applicable subheading for the Cabozantinib in bulk powder form will be 2933.49.2600, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Heterocyclic compounds with nitrogen hetero-atom(s)only: Compounds containing in the structure a quinoline or isoquinoline ring-system (whether or not hydrogenated), not further fused: Other: Other: Drugs: Other.” The rate of duty will be 6.5 percent ad valorem. Currently, Cobozantinib is not listed in the Pharmaceutical Appendix to the Harmonized Tariff Schedule. Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided on the World Wide Web at https://hts.usitc.gov/current. This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov. This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Judy Lee at [email protected]. Sincerely, Steven A. Mack Director National Commodity Specialist Division
More rulings on the same tariff codes
The tariff classification of Lenvatinib Mesylate (CAS No. 857890-39-2) in bulk powder form, from Italy
The tariff classification of Lenvatinib Mesylate (CAS No. 857890-39-2) in bulk form, from India
The tariff classification of Besifloxacin Hydrochloride (CAS No. 405165-61-9) in bulk form, from India
The tariff classification of Solifenacin Succinate (CAS 242478-38-2), in bulk powder form, from Spain
The tariff classification of Cabozantinib s-Malate (CAS-1140909-48-3), imported in bulk form and in dosage form
The tariff classification of Moxifloxacin Hydrochloride (CAS-186826-86-8) in bulk form, from Italy
The tariff classification of Quinapril HCL (CAS-82586-55-8) in bulk, from India
The tariff classification of Butorphanol Tartrate (CAS- 58786-99-5) imported in bulk form, from India
The tariff classification of Cisatracurium Besylate (CAS# 96946-42-8) in bulk form, from Italy
The tariff classification of Investigational New Drug VX-770 (N-(2,4-Di-tert-butyl-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide) in bulk and in dosage forms, from Portugal and the United Kingdom
Searching CBP rulings the smart way
TariffLens semantically searches all 200,000+ CBP rulings, surfaces the ones that actually match your product, and builds defensible classifications backed by ruling citations.
Book a demo →